Cinaciguat

DB16126InvestigationalSmall molecule

Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients...

Formula / weight: C₃₆H₃₉NO₅ · 565.71 g/mol (avg)
Code names: BAY 58-2667

Resolves to

Compound

UNII59K0Y58UADCAS329773-35-5ChEMBLCHEMBL1236936ChEBI142433

Structure

InChIKeyWPYWMXNXEZFMAK-UHFFFAOYSA-NSMILESOC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC1=CC=C(C=C1)C(O)=O

Targets

Q02153GUCY1B1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Cinaciguat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account